High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
Document Type
Article
Publication Title
Journal of contemporary brachytherapy
Abstract
PURPOSE: To evaluate our institutional experience combining carboplatin-paclitaxel (C/T) chemotherapy with high-dose-rate (HDR) intra-vaginal brachytherapy (IVB) following comprehensive surgical staging in localized uterine serous carcinoma (USC). MATERIAL AND METHODS: Institutional chart review identified 56 patients with FIGO 2009 stage I-II USC treated between 2000-2010. Patients underwent total hysterectomy, bilateral salpingo-oopherectomy, and comprehensive surgical staging including pelvic and para-aortic lymph node dissection, omentectomy, and peritoneal cytology. Chemotherapy was 6 cycles of C/T, and the IVB dose was 14 Gy in 2 fractions, prescribed to 0.5 cm from the cylinder surface. Kaplan-Meier methods were used to estimate recurrence-free survival (RFS) and overall survival (OS). RESULTS: The median follow-up time was 49 months (range: 9-145). The 5-yr RFS and OS were 85% and 93%, respectively. In all cases of recurrence (n = 8), the first site of failure was extra-pelvic. There were no isolated vaginal recurrences, however, there was one vaginal apex recurrence recorded at 19 months in a patient with simultaneous lung metastases. Thus, the 2-year vaginal RFS was 98%. CONCLUSIONS: Excellent vaginal/pelvic control rates were observed. Further study of HDR brachytherapy dose and fractionation in combination with chemotherapy is worthwhile.
First Page
35
Last Page
40
DOI
10.5114/jcb.2015.48539
Publication Date
2-1-2015
Recommended Citation
Damast, Shari; Higgins, Susan A.; Ratner, Elena; De Leon, Maria C.; Mani, Sheida; Silasi, Dan-Arin; Azodi, Masoud; Santin, Alessandro; Rutherford, Thomas; and Schwartz, Peter E., "High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma" (2015). Obstetrics and Gynecology. 122.
https://scholar.bridgeporthospital.org/obgyn/122
Identifier
25829935 (pubmed); PMC4371058 (pmc); 10.5114/jcb.2015.48539 (doi); 24399 (pii)